However, developing ATM inhibitors has been challenging due to ATM’s essential role in normal cell DNA repair (Pilié et al., 2019), and their effectiveness is limited in cancers where alternative pathways, like ATR, can compensate for the loss of ATM function. Here, ATR is linked to cancer.